Ebraam B. Kamel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ebraam B. Kamel has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Maya S. Eissa
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt
5 shared publications Israa M. Nour
4 shared publicationsMohamed Badrawy
4 shared publicationsEman A. Bahgat
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
3 shared publicationsHanaa Saleh
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
3 shared publicationsHisham Hashem
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
3 shared publications
Latest Publications
- 30 June 2026
- Published by Wiley in Luminescence
- Vol. 41 (7) , e70547
Balancing Analytical Performance and Sustainability: AGSA and MA Tools‐Assessed Fluorimetric Determination of Co‐Administered Tadalafil and Omeprazole
A sensitive and environmentally sustainable spectrofluorimetric method was developed for the simultaneous determination of tadalafil (TAD) and omeprazole (OME) in pharmaceutical formulations and spiked human plasma. The method relies on the native fluorescence of TAD measured at λ_ex 280 nm and λ_em 330 nm, while OME was derivatized with 4‐chloro‐7‐nitrobenzo‐2‐oxa‐1,3‐diazole (NBD‐Cl) to form a highly fluorescent derivative measured at λ_ex 465 nm and λ_em 535 nm. Experimental variables affecting fluorescence intensity were systematically optimized. The method showed excellent linearity over the concentration ranges of 4–40 ng mL −1 for TAD and 30–2000 ng mL −1 for OME, with limits of detection of 1.15 and 8.94 ng mL −1 , respectively. The method was validated according to ICH guidelines and demonstrated satisfactory accuracy, precision, and selectivity. A successful application was achieved for the analysis of pharmaceutical dosage forms and spiked human plasma samples. The environmental sustainability of the method was evaluated using the Analytical Green Sustainability Assessment (AGSA) and the Multi‐color Assessment (MA) tool, confirming the excellent greenness and overall sustainability of the proposed analytical approach. The developed method provides a rapid, sensitive, and eco‐friendly alternative for routine quality control and bioanalytical applications.
- 30 June 2026
- Published by Wiley in Luminescence
- Vol. 41 (7) , e70547
Balancing Analytical Performance and Sustainability: AGSA and MA Tools‐Assessed Fluorimetric Determination of Co‐Administered Tadalafil and Omeprazole
A sensitive and environmentally sustainable spectrofluorimetric method was developed for the simultaneous determination of tadalafil (TAD) and omeprazole (OME) in pharmaceutical formulations and spiked human plasma. The method relies on the native fluorescence of TAD measured at λ_ex 280 nm and λ_em 330 nm, while OME was derivatized with 4‐chloro‐7‐nitrobenzo‐2‐oxa‐1,3‐diazole (NBD‐Cl) to form a highly fluorescent derivative measured at λ_ex 465 nm and λ_em 535 nm. Experimental variables affecting fluorescence intensity were systematically optimized. The method showed excellent linearity over the concentration ranges of 4–40 ng mL −1 for TAD and 30–2000 ng mL −1 for OME, with limits of detection of 1.15 and 8.94 ng mL −1 , respectively. The method was validated according to ICH guidelines and demonstrated satisfactory accuracy, precision, and selectivity. A successful application was achieved for the analysis of pharmaceutical dosage forms and spiked human plasma samples. The environmental sustainability of the method was evaluated using the Analytical Green Sustainability Assessment (AGSA) and the Multi‐color Assessment (MA) tool, confirming the excellent greenness and overall sustainability of the proposed analytical approach. The developed method provides a rapid, sensitive, and eco‐friendly alternative for routine quality control and bioanalytical applications.
- Open Access
- 13 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Validated comprehensive RP HPLC approach for separation and quantification of solifenacin and mirabegron in the presence of their degradation products
A rapid and efficient High-Performance Liquid Chromatography (HPLC) method was developed and optimized for the separation and quantification of solifenacin succinate (SOL), mirabegron (MIR), solifenacin impurities A (SOL IMP A), I (SOL IMP I) and mirabegron metabolite (MIR MET) using a C 18 column. Solifenacin succinate is a muscarinic receptor antagonist used in the treatment of overactive bladder (OAB) by reducing bladder muscle contractions, while mirabegron, a β3-adrenergic agonist, works by relaxing the bladder smooth muscle to improve storage capacity and reduce symptoms of OAB. However, the presence of impurities and metabolites, such as solifenacin impurities A, I, and E, can negatively impact the safety and efficacy of these drugs, potentially causing adverse effects such as increased toxicity, altered pharmacodynamics, or diminished therapeutic effectiveness. The method employed an isocratic elution system with a mobile phase of water containing 0.1% formic acid (solvent A) and acetonitrile with 0.1% formic acid (solvent B), using a C 18 column (4.6 mm × 100 mm, 3 μm) at a flow rate of 1.2 mL/min and a column temperature of 30 °C. UV detection at 220 nm allowed for the efficient separation of all analytes within 10.5 min, with excellent resolution between solifenacin succinate, mirabegron, their metabolites, and impurities. The linearity range for solifenacin succinate and mirabegron was 1–100 µg/mL, and solifenacin impurities A, I, and E, and mirabegron metabolite exhibited linearity ranges of 0.1–10 and 0.1–50 µg/mL, respectively. Validation studies confirmed good precision (RSD < 2%) and accuracy, making this method suitable for routine quality control and pharmacokinetic studies. This validated HPLC method offers a reliable tool for monitoring the purity of solifenacin succinate and mirabegron, ensuring their therapeutic efficacy and safety by quantifying both the active compounds and potentially harmful impurities or metabolites.
- 13 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessValidated comprehensive RP HPLC approach for separation and quantification of solifenacin and mirabegron in the presence of their degradation products
A rapid and efficient High-Performance Liquid Chromatography (HPLC) method was developed and optimized for the separation and quantification of solifenacin succinate (SOL), mirabegron (MIR), solifenacin impurities A (SOL IMP A), I (SOL IMP I) and mirabegron metabolite (MIR MET) using a C 18 column. Solifenacin succinate is a muscarinic receptor antagonist used in the treatment of overactive bladder (OAB) by reducing bladder muscle contractions, while mirabegron, a β3-adrenergic agonist, works by relaxing the bladder smooth muscle to improve storage capacity and reduce symptoms of OAB. However, the presence of impurities and metabolites, such as solifenacin impurities A, I, and E, can negatively impact the safety and efficacy of these drugs, potentially causing adverse effects such as increased toxicity, altered pharmacodynamics, or diminished therapeutic effectiveness. The method employed an isocratic elution system with a mobile phase of water containing 0.1% formic acid (solvent A) and acetonitrile with 0.1% formic acid (solvent B), using a C 18 column (4.6 mm × 100 mm, 3 μm) at a flow rate of 1.2 mL/min and a column temperature of 30 °C. UV detection at 220 nm allowed for the efficient separation of all analytes within 10.5 min, with excellent resolution between solifenacin succinate, mirabegron, their metabolites, and impurities. The linearity range for solifenacin succinate and mirabegron was 1–100 µg/mL, and solifenacin impurities A, I, and E, and mirabegron metabolite exhibited linearity ranges of 0.1–10 and 0.1–50 µg/mL, respectively. Validation studies confirmed good precision (RSD < 2%) and accuracy, making this method suitable for routine quality control and pharmacokinetic studies. This validated HPLC method offers a reliable tool for monitoring the purity of solifenacin succinate and mirabegron, ensuring their therapeutic efficacy and safety by quantifying both the active compounds and potentially harmful impurities or metabolites.
- 28 August 2025
- Published by Wiley in Luminescence
- Vol. 40 (9) , e70294
Eco‐Friendly Simultaneous Quantification of Domperidone and Safinamide by Spectral Resolution using deconvoluted Synchronous Fluorescence: Application to Spiked Human Plasma
A novel, eco‐friendly deconvoluted synchronous spectrofluorimetric method has been developed and validated for the simultaneous determination of domperidone (DOM) and safinamide (SAF), a potential combination used to address Parkinson's disease–associated gastrointestinal dysfunction. Their combined administration necessitates a reliable analytical method for therapeutic monitoring and formulation quality control. Traditional spectrofluorimetric techniques fail to resolve the significant spectral overlap between these two compounds. In this study, a deconvoluted synchronous spectrofluorimetric method, using Fourier self‐deconvolution at Δλ = 30 nm, successfully resolved the overlapping fluorescence spectra without any need for physical separation. It showed excellent linearity (DOM: 10–1500 ng/mL, SAF: 50–2000 ng/mL), with low LOD (2.75 ng/mL for DOM and 11.77 ng/mL for SAF), high recovery rates in both pharmaceutical forms and spiked human plasma (above 90%), and outstanding selectivity and robustness. Sustainability of the current method was assessed using spider chart measure, green solvent selection tool, Analytical GREEnness Metric, Modified Green Analytical Procedure index, and Blue Applicability Grade Index. The proposed technique represents a simple, sensitive, and sustainable tool for routine analysis of this therapeutically significant drug pair.
- 28 August 2025
- Published by Wiley in Luminescence
- Vol. 40 (9) , e70294
Eco‐Friendly Simultaneous Quantification of Domperidone and Safinamide by Spectral Resolution using deconvoluted Synchronous Fluorescence: Application to Spiked Human Plasma
A novel, eco‐friendly deconvoluted synchronous spectrofluorimetric method has been developed and validated for the simultaneous determination of domperidone (DOM) and safinamide (SAF), a potential combination used to address Parkinson's disease–associated gastrointestinal dysfunction. Their combined administration necessitates a reliable analytical method for therapeutic monitoring and formulation quality control. Traditional spectrofluorimetric techniques fail to resolve the significant spectral overlap between these two compounds. In this study, a deconvoluted synchronous spectrofluorimetric method, using Fourier self‐deconvolution at Δλ = 30 nm, successfully resolved the overlapping fluorescence spectra without any need for physical separation. It showed excellent linearity (DOM: 10–1500 ng/mL, SAF: 50–2000 ng/mL), with low LOD (2.75 ng/mL for DOM and 11.77 ng/mL for SAF), high recovery rates in both pharmaceutical forms and spiked human plasma (above 90%), and outstanding selectivity and robustness. Sustainability of the current method was assessed using spider chart measure, green solvent selection tool, Analytical GREEnness Metric, Modified Green Analytical Procedure index, and Blue Applicability Grade Index. The proposed technique represents a simple, sensitive, and sustainable tool for routine analysis of this therapeutically significant drug pair.
- Open Access
- 6 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Stability-indicating spectrophotometric quantification of safinamide in the presence of its possible degradation product
In recent times, a truly exquisite pharmaceutical marvel has graced the world of medicine, known as Safinamide (SAF). This opulent creation has been specifically tailored to cater to the needs of individuals afflicted with Parkinson’s disease (PD), an esteemed neurological condition renowned for its regal ability to impede motor skills, coordination, and equilibrium. It is highly improbable that degradation products of pharmaceutical components would significantly compromise efficiency and safety of a drug during its shelf life. Pharmaceutical analysis requires a variety of stability tests to be conducted under distinct conditions. As a result, there was an increased need for the development of an analytical methodology capable of reliably separating and quantifying degradants and impurities that might be found in pharmaceuticals. In this study, we have developed two efficient and straightforward spectrophotometric methodologies for the concurrent estimation of SAF and its degradation product (SAF DEG), which is the main acid hydrolysis product. The confirmation of degradation product build-up by the use of several analytical techniques, including infrared spectroscopy (IR), and mass spectrometry (MS) investigations. The present methodologies have been validated for linearity within the concentration range of 5–30 µg/ml for SAF, and 5–15 µg/mL, 2–15 µg/ml for SAF DEG for fourier self-deconvolution (FSD) and dual wavelength (DW) methods, respectively. The originality of these techniques lies in their status as the first stability-indicating spectrophotometric procedures that are both environmentally friendly. Moreover, the process of obtaining pure SAF DEG offers substantial economic benefits by obviating the need to acquire a costly constituent. The use of intelligent techniques was employed to analyze the pharmaceutical dosage form, potentially offering significant advantages to the pharmaceutical industry.
- 6 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Open AccessStability-indicating spectrophotometric quantification of safinamide in the presence of its possible degradation product
In recent times, a truly exquisite pharmaceutical marvel has graced the world of medicine, known as Safinamide (SAF). This opulent creation has been specifically tailored to cater to the needs of individuals afflicted with Parkinson’s disease (PD), an esteemed neurological condition renowned for its regal ability to impede motor skills, coordination, and equilibrium. It is highly improbable that degradation products of pharmaceutical components would significantly compromise efficiency and safety of a drug during its shelf life. Pharmaceutical analysis requires a variety of stability tests to be conducted under distinct conditions. As a result, there was an increased need for the development of an analytical methodology capable of reliably separating and quantifying degradants and impurities that might be found in pharmaceuticals. In this study, we have developed two efficient and straightforward spectrophotometric methodologies for the concurrent estimation of SAF and its degradation product (SAF DEG), which is the main acid hydrolysis product. The confirmation of degradation product build-up by the use of several analytical techniques, including infrared spectroscopy (IR), and mass spectrometry (MS) investigations. The present methodologies have been validated for linearity within the concentration range of 5–30 µg/ml for SAF, and 5–15 µg/mL, 2–15 µg/ml for SAF DEG for fourier self-deconvolution (FSD) and dual wavelength (DW) methods, respectively. The originality of these techniques lies in their status as the first stability-indicating spectrophotometric procedures that are both environmentally friendly. Moreover, the process of obtaining pure SAF DEG offers substantial economic benefits by obviating the need to acquire a costly constituent. The use of intelligent techniques was employed to analyze the pharmaceutical dosage form, potentially offering significant advantages to the pharmaceutical industry.
- 9 December 2023
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 107 (2) , 362-370
Exciting Advances in Sustainable Spectrophotometric Micro-Quantitation of an Innovative Painkiller “Tramadol and Celecoxib” Mixture in the Presence of a Toxic Impurity, Promoting Greenness and Whiteness Studies
Tramadol (TRM) and celecoxib (CLX) are a novel mixture that helps relieve impetuous, acute pain when other painkillers have no action. It is also reported that the currently studied drugs, tramadol and celecoxib, are used to control COVID-19 symptoms. The current work highlights three important pillars of modern pharmaceutical analysis, which are as follows; impurity profiling, greenness/whiteness studies and simplicity accompanied by sensitivity. Since 4-methyl acetophenone inhibits the human carbonyl reductase enzyme (type I), and since this compound may pose a health risk, it is crucial to regulate its concentration in all dosage forms of CLX. Two simple and green spectrophotometric methods were developed, namely; Third Derivative (D3) and Fourier Self Deconvulation (FSD) for resolving severely overlapped spectra of tramadol and celecoxib in the presence of 4-methyl acetophenone (4-MAP) as a process-related impurity in their novel tablet combination. The two approaches showed acceptable linearity with an excellent correlation coefficient. Simply, for both methods tramadol was measured when celecoxib and 4-methyl acetophenone were zero-crossing. The same procedure was applied for measuring celecoxib and its process-related impurity; 4-methyl acetophenone. The methodologies developed were thoroughly validated in compliance with ICH guidelines. Student t and F-tests revealed no statistically substantial variation among the current methods and the reported method. No spectrophotometric methods have been published for the simultaneous analysis of TRM and CLX along with 4-MAP. As a result, the newly developed spectrophotometric approaches hold great relevance and originality in the field of pharmaceutical analysis.
- 9 December 2023
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 107 (2) , 362-370
Exciting Advances in Sustainable Spectrophotometric Micro-Quantitation of an Innovative Painkiller “Tramadol and Celecoxib” Mixture in the Presence of a Toxic Impurity, Promoting Greenness and Whiteness Studies
Tramadol (TRM) and celecoxib (CLX) are a novel mixture that helps relieve impetuous, acute pain when other painkillers have no action. It is also reported that the currently studied drugs, tramadol and celecoxib, are used to control COVID-19 symptoms. The current work highlights three important pillars of modern pharmaceutical analysis, which are as follows; impurity profiling, greenness/whiteness studies and simplicity accompanied by sensitivity. Since 4-methyl acetophenone inhibits the human carbonyl reductase enzyme (type I), and since this compound may pose a health risk, it is crucial to regulate its concentration in all dosage forms of CLX. Two simple and green spectrophotometric methods were developed, namely; Third Derivative (D3) and Fourier Self Deconvulation (FSD) for resolving severely overlapped spectra of tramadol and celecoxib in the presence of 4-methyl acetophenone (4-MAP) as a process-related impurity in their novel tablet combination. The two approaches showed acceptable linearity with an excellent correlation coefficient. Simply, for both methods tramadol was measured when celecoxib and 4-methyl acetophenone were zero-crossing. The same procedure was applied for measuring celecoxib and its process-related impurity; 4-methyl acetophenone. The methodologies developed were thoroughly validated in compliance with ICH guidelines. Student t and F-tests revealed no statistically substantial variation among the current methods and the reported method. No spectrophotometric methods have been published for the simultaneous analysis of TRM and CLX along with 4-MAP. As a result, the newly developed spectrophotometric approaches hold great relevance and originality in the field of pharmaceutical analysis.
- Open Access
- 15 March 2023
- Published by Springer Nature in BMC Chemistry
- Vol. 17 (1) , 1-10
HPLC-DAD technique for the quantification of a recently approved anti-diabetic triple combination along with two toxic official impurities: Toxicity confirmation aided by molecular docking application
Background: Gliflozins and gliptins are two distinct groups of pharmacological drugs that reduce blood glucose levels in individuals with type II diabetes in various ways that may perform their functions harmoniously. Trijardy® tablet, which contains empagliflozin, linagliptin, and metformin, was recently approved. The scientific database does not yet have a method that is sensitive enough to quantify the aforementioned medications in the presence of metformin official toxic impurities melamine and cyanoguanidine. Molecular docking modeling was utilized in this work to further prove the toxicity of melamine. Methods: The five analytes listed before were quantified using RP-HPLC-diode array detector and a Zorbax® C8 column (4.6 × 250 mm, 5 μm) with isocratic mobile phase composed of acetonitrile and 0.05 M potassium dihydrogen phosphate buffer, which had been treated by ?-phosphoric acid to restore a pH of 4.0 (90:10, v/v) at a flow rate of 1.2 mL/min and the eluted peaks were scanned at 250 nm. Conclusion: The utilization of the simplest isocratic elution mode give the current technique a significant time-and cost-saving benefit. The current method can quantify the triple therapy agents in the presence of each other as well as with two official toxic impurities of metformin in one short analytical run.
- 15 March 2023
- Published by Springer Nature in BMC Chemistry
- Vol. 17 (1) , 1-10
Open AccessHPLC-DAD technique for the quantification of a recently approved anti-diabetic triple combination along with two toxic official impurities: Toxicity confirmation aided by molecular docking application
Background: Gliflozins and gliptins are two distinct groups of pharmacological drugs that reduce blood glucose levels in individuals with type II diabetes in various ways that may perform their functions harmoniously. Trijardy® tablet, which contains empagliflozin, linagliptin, and metformin, was recently approved. The scientific database does not yet have a method that is sensitive enough to quantify the aforementioned medications in the presence of metformin official toxic impurities melamine and cyanoguanidine. Molecular docking modeling was utilized in this work to further prove the toxicity of melamine. Methods: The five analytes listed before were quantified using RP-HPLC-diode array detector and a Zorbax® C8 column (4.6 × 250 mm, 5 μm) with isocratic mobile phase composed of acetonitrile and 0.05 M potassium dihydrogen phosphate buffer, which had been treated by ?-phosphoric acid to restore a pH of 4.0 (90:10, v/v) at a flow rate of 1.2 mL/min and the eluted peaks were scanned at 250 nm. Conclusion: The utilization of the simplest isocratic elution mode give the current technique a significant time-and cost-saving benefit. The current method can quantify the triple therapy agents in the presence of each other as well as with two official toxic impurities of metformin in one short analytical run.